BioSpace News Archive

Cipla Limited announced the launch of remdesivir under its brand name CIPREMI.

Tetraphase Pharmaceuticals, Inc. announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company to acquire Tetraphase for $43.0 million in cash

Certain members of Biolase’s executive management and directors have indicated their intent to subscribe to the rights offering

Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B.

KEYTRUDA Is Now Approved Across Five indications for Three Different Types of Cancer in China and Is First Anti-PD-1 Therapy Approved for Esophageal Cancer

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Allen Melemed, M.D., M.B.A., as Chief Medical Officer.

TELA Bio, Inc. announced that the company will be added to the Russell 2000® Index at the conclusion of the Russell U.S. Indices annual reconstitution, effective after the U.S. market opens on June 26, 2020.

Resverlogix Corp. is pleased to announce that the U.S. Food & Drug Administration has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.

As residents across Hawaii continue to face challenges beyond medical care due to the COVID-19 pandemic, ‘Ohana Health Plan, a subsidiary of Centene Corporation, a leading multi-national healthcare company, is partnering with community-based organizations and other programs to provide access to food and other essential supplies across Oahu.